Intuitive Surgical Inc (ISRG) company profile
Close on Nov 17, 2026Market cap $149.24BP/E 52.1Yield –
About Intuitive Surgical
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
Intuitive Surgical develops and provides robotic-assisted surgical platforms and diagnostic technologies designed to advance minimally invasive healthcare. The company manufactures the da Vinci surgical system for a wide range of soft-tissue procedures and the Ion endoluminal system for minimally invasive lung biopsies. Beyond primary robotic hardware, its portfolio encompasses specialized instruments, advanced stapling and energy tools, sterile accessories, educational simulation software, and analytics services. Intuitive primarily serves hospitals, healthcare systems, surgeons, and procedural care teams across general surgery, urology, gynecology, cardiothoracic, and head and neck specialties.
The company deploys its surgical and diagnostic platforms internationally across the United States and global markets. Intuitive supports its customer base through an infrastructure of field service engineers situated throughout the United States, Canada, Europe, and Asia, alongside distributor partnerships worldwide. The organization also maintains dedicated training centers where staff instruct clinicians and care teams on its technologies. The provided text does not mention the location of the company's headquarters.
Summary of the business section of Intuitive Surgical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Intuitive Surgical Inc
- Founded
- 1995
- Headquarters
- Sunnyvale, CA
- Address
- 1020 Kifer Road 94086
- Phone
- (408) 523-2100
- Website
- intuitive.com
- Employees
- 17,021, Dec 31, 2025
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- ISRG
- Exchange
- Nasdaq
- IPO date
- Jun 16, 2000
- Shares outstanding
- 347M, Oct 15, 2026
- Public float
- $193.90B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 3-for-1, Oct 5, 2021; 3-for-1, Oct 6, 2017; 1-for-2 reverse, Jul 1, 2003
- SEC CIK
- 1035267
- CUSIP
- 46120E602
- ISIN
- US46120E6023
- FIGI
- BBG000BJPDZ1
- Share class FIGI
- BBG001S7XR78
- LEI
- 54930052SRG011710797
- EIN
- 77-0416458
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David J. Rosa | Chief Executive Officer (CEO), Director | 247,803 |
| Gary Loeb | EVP & Chief Legal and Complian | 6,236 |
| Mark Brosius | EVP & Chief Mfg and Supply Cha | 457 |
| Fredrik Widman | VP Corporate Controller | 1,026 |
| Patricia L. Wadors | SVP Chief Human Resources Offi | 0 |
| Iman Jeddi | SVP & GM da Vinci Platforms & | 38,737 |
| Myriam Curet | EVP & Chief Medical Officer | 514 |
| Henry L. Charlton | EVP & Chief Commercial and Mkt | 5,972 |
| Jamie Samath | EVP & CFO & Enterprise Technol | 15,366 |
| Brian Edward Miller | EVP & Chief Digital Officer | 5,758 |
| Robert DeSantis | EVP & Chief Strategy & Corp Op | 5,412 |
| Craig H. Barratt | Director | 27,948 |
| Gary S. Guthart | Director | 1,258,781 |
| Amy L. Ladd | Director | 179 |
| Lewis Chew | Director | 1,314 |
| Sreelakshmi Kolli | Director | 1,510 |
| Amal M. Johnson | Director | 13,545 |
| Keith R. Leonard | Director | 901 |
| Jami K. Nachtsheim | Director | 6,902 |
| Joseph C. Beery | Director | 3,641 |
| Monica P. Reed | Director | 2,876 |
| Mark J. Rubash | Director | 16,790 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr.Guthart | $18.09M | $23.85M | $6.44M | $287 | $103 |
| FY2025 Mr.Rosa | $21.00M | $26.38M | $6.44M | $287 | $103 |
| FY2024 | $18.20M | $42.63M | $8.37M | $265 | $104 |
| FY2023 | $12.45M | $22.73M | $6.88M | $171 | $99 |
| FY2022 | $10.35M | $1.61M | $4.99M | $135 | $105 |
| FY2021 | $8.06M | $17.46M | $4.46M | $182 | $137 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| David J. Rosa Chief Executive Officer | $858.75K | $18.67M | $1.37M | $90.00K | $21.00M | +53% |
| Gary S. Guthart, Ph.D. Executive Chair of the Board of Directors | $866.25K | $15.95M | $886.16K | $387.87K | $18.09M | -1% |
| Jamie E. Samath Executive Vice President, Chief Financial Officer and Enterprise Technology Leader | $683.00K | $6.91M | $786.82K | $12.00K | $8.40M | +19% |
| Henry L. Charlton Executive Vice President and Chief Commercial and Marketing Officer | $670.00K | $4.79M | $771.84K | $12.00K | $6.24M | -4% |
| Gary H. Loeb Executive Vice President and Chief Legal and Compliance Officer | $615.00K | $4.25M | $708.48K | $12.00K | $5.59M | – |
| Mark P. Brosius Senior Vice President and Chief Manufacturing and Supply Chain Officer | $534.35K | $4.52M | $462.24K | $22.00K | $5.54M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 17,021 full-time employees, with approximately 2,288 in research and development, 7,625 in manufacturing operations, 4,837 in commercial and service operations, and 2,271 in administrative activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 4, 2014 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 14, 2014 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 28, 2003 | Merger | Registration of securities for a merger or exchange offer (S-4) |
See a number that looks wrong?